Absolute eosinophil count(AEC) ≥ 1500/mL인 환자에서 초기 치료를 결정하는 데 고려해야 하는 요인 → 임상양상의 acuity와 nature
대부분의 HES에서 systemic glucocorticoids (GCs)가 1st-line agent
초기 평가에서 다른 대안치료를 필요로 하는 경우를 규명해 내는 것이 중요
1. HES due to a secondary cause for which specific therapy is available (associated HES)
2. myeloid neoplasms associated with imatinib-sensitive mutations, including FIP1L1-PDGFRA, or known to be GC resistant
3. overlap syndromes that can be managed with topical agents, such as eosinophilic esophagitis. Equally important is the decision to treat or observe asymptomatic patients with AEC ≥ 1500/mL and no features of myeloid hypereosinophilic syndrome (MHES) or evidence of end organ manifestations (ie, hypereosinophilia of unknown significance), because biomarkers that predict disease progression are lacking.

Omitted

[스테로이드] 과호산구증후군(Hypereosinophilic syndrome) 회원